U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H24N2O
Molecular Weight 260.3746
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROPINIROLE

SMILES

CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2

InChI

InChIKey=UHSKFQJFRQCDBE-UHFFFAOYSA-N
InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)

HIDE SMILES / InChI

Molecular Formula C16H24N2O
Molecular Weight 260.3746
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/requip-xl-ropinirole-343051 | https://www.drugs.com/cdi/ropinirole.html | https://www.drugbank.ca/drugs/DB00268

Ropinirole (INN; trade names Requip, Repreve, Ronirol, Adartrel) is a dopamine agonist of the non-ergoline class of medications, used in the treatment of Parkinson's disease and restless legs syndrome. Although the precise mechanism of action of ropinirole as a treatment for Parkinson's disease is unknown, it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that ropinirole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum. Ropinirole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The mechanism of ropinirole-induced postural hypotension is presumed to be due to a D2 -mediated blunting of the noradrenergic response to standing and subsequent decrease in peripheral vascular resistance. Ropinirole can cause nausea, dizziness, hallucinations, orthostatic hypotension, and sudden sleep attacks during the daytime. Unusual side effects specific to D3 agonists such as ropinirole and pramipexole can include hypersexuality, punding, and compulsive gambling, even in patients without a history of these behaviors.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
83.0 nM [EC50]
19.2 nM [EC50]
100.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
REQUIP

Approved Use

Parkinson's Disease Ropinirole tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. The effectiveness of ropinirole tablet was demonstrated in randomized, controlled trials in patients with early Parkinson's disease who were not receiving concomitant L-dopa therapy as well as in patients with advanced disease on concomitant L-dopa (see CLINICAL PHARMACOLOGY: Clinical Trials). Restless Legs Syndrome Ropinirole tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). Key diagnostic criteria for RLS are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. Difficulty falling asleep may frequently be associated with moderate-to-severe RLS.

Launch Date

8.746272E11
Primary
REQUIP

Approved Use

Parkinson's Disease Ropinirole tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. The effectiveness of ropinirole tablet was demonstrated in randomized, controlled trials in patients with early Parkinson's disease who were not receiving concomitant L-dopa therapy as well as in patients with advanced disease on concomitant L-dopa (see CLINICAL PHARMACOLOGY: Clinical Trials). Restless Legs Syndrome Ropinirole tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). Key diagnostic criteria for RLS are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. Difficulty falling asleep may frequently be associated with moderate-to-severe RLS.

Launch Date

8.746272E11
Primary
REQUIP

Approved Use

Parkinson's Disease Ropinirole tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. The effectiveness of ropinirole tablet was demonstrated in randomized, controlled trials in patients with early Parkinson's disease who were not receiving concomitant L-dopa therapy as well as in patients with advanced disease on concomitant L-dopa (see CLINICAL PHARMACOLOGY: Clinical Trials). Restless Legs Syndrome Ropinirole tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). Key diagnostic criteria for RLS are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. Difficulty falling asleep may frequently be associated with moderate-to-severe RLS.

Launch Date

8.746272E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.01 ng/mL
2 mg 3 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ROPINIROLE HYDROCHLORIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
6.53 ng/mL
2 mg 3 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ROPINIROLE HYDROCHLORIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
25.9 ng × h/mL
2 mg 3 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ROPINIROLE HYDROCHLORIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
29.1 ng × h/mL
2 mg 3 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ROPINIROLE HYDROCHLORIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6 h
unknown, oral
ROPINIROLE HYDROCHLORIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
60%
unknown, oral
ROPINIROLE HYDROCHLORIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 1
Health Status: unhealthy
Condition: Parkinson's disease with severe dyskinesias
Population Size: 1
Sources:
435 mg 1 times / day multiple, oral
Overdose
Dose: 435 mg, 1 times / day
Route: oral
Route: multiple
Dose: 435 mg, 1 times / day
Sources: Page: p. 18
unhealthy
Other AEs: Nausea, Dizziness...
Other AEs:
Nausea
Dizziness
Claustrophobia
Chorea
Palpitations
Asthenia
Nightmares
Hyperhidrosis
Visual hallucinations
Sources: Page: p. 18
0.5 mg 2 times / day steady, oral
Recommended
Dose: 0.5 mg, 2 times / day
Route: oral
Route: steady
Dose: 0.5 mg, 2 times / day
Sources:
unhealthy
n = 157
Health Status: unhealthy
Condition: Parkinson’s disease
Population Size: 157
Sources:
Disc. AE: Nausea, Dizziness...
AEs leading to
discontinuation/dose reduction:
Nausea (2%)
Dizziness (2%)
Sources:
24 mg 1 times / day steady, oral
Recommended
Dose: 24 mg, 1 times / day
Route: oral
Route: steady
Dose: 24 mg, 1 times / day
Sources:
unhealthy
n = 61
Health Status: unhealthy
Condition: Parkinson's disease
Population Size: 61
Sources:
AEs

AEs

AESignificanceDosePopulation
Asthenia
435 mg 1 times / day multiple, oral
Overdose
Dose: 435 mg, 1 times / day
Route: oral
Route: multiple
Dose: 435 mg, 1 times / day
Sources: Page: p. 18
unhealthy
Chorea
435 mg 1 times / day multiple, oral
Overdose
Dose: 435 mg, 1 times / day
Route: oral
Route: multiple
Dose: 435 mg, 1 times / day
Sources: Page: p. 18
unhealthy
Claustrophobia
435 mg 1 times / day multiple, oral
Overdose
Dose: 435 mg, 1 times / day
Route: oral
Route: multiple
Dose: 435 mg, 1 times / day
Sources: Page: p. 18
unhealthy
Dizziness
435 mg 1 times / day multiple, oral
Overdose
Dose: 435 mg, 1 times / day
Route: oral
Route: multiple
Dose: 435 mg, 1 times / day
Sources: Page: p. 18
unhealthy
Hyperhidrosis
435 mg 1 times / day multiple, oral
Overdose
Dose: 435 mg, 1 times / day
Route: oral
Route: multiple
Dose: 435 mg, 1 times / day
Sources: Page: p. 18
unhealthy
Nausea
435 mg 1 times / day multiple, oral
Overdose
Dose: 435 mg, 1 times / day
Route: oral
Route: multiple
Dose: 435 mg, 1 times / day
Sources: Page: p. 18
unhealthy
Nightmares
435 mg 1 times / day multiple, oral
Overdose
Dose: 435 mg, 1 times / day
Route: oral
Route: multiple
Dose: 435 mg, 1 times / day
Sources: Page: p. 18
unhealthy
Palpitations
435 mg 1 times / day multiple, oral
Overdose
Dose: 435 mg, 1 times / day
Route: oral
Route: multiple
Dose: 435 mg, 1 times / day
Sources: Page: p. 18
unhealthy
Visual hallucinations
435 mg 1 times / day multiple, oral
Overdose
Dose: 435 mg, 1 times / day
Route: oral
Route: multiple
Dose: 435 mg, 1 times / day
Sources: Page: p. 18
unhealthy
Dizziness 2%
Disc. AE
0.5 mg 2 times / day steady, oral
Recommended
Dose: 0.5 mg, 2 times / day
Route: oral
Route: steady
Dose: 0.5 mg, 2 times / day
Sources:
unhealthy
n = 157
Health Status: unhealthy
Condition: Parkinson’s disease
Population Size: 157
Sources:
Nausea 2%
Disc. AE
0.5 mg 2 times / day steady, oral
Recommended
Dose: 0.5 mg, 2 times / day
Route: oral
Route: steady
Dose: 0.5 mg, 2 times / day
Sources:
unhealthy
n = 157
Health Status: unhealthy
Condition: Parkinson’s disease
Population Size: 157
Sources:
PubMed

PubMed

TitleDatePubMed
Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.
2000 Mar
High-dose therapy with ropinirole in patients with Parkinson's disease.
2001
Sleep disorders in patients with Parkinson's disease: epidemiology and management.
2001
Are dopamine receptor agonists neuroprotective in Parkinson's disease?
2001
The Posturo-Locomotion-Manual Test. A simple method for the characterization of neurological movement disturbances.
2001
Dopamine agonists.
2001
Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism.
2001 Apr 27
Iontophoretic delivery of ropinirole hydrochloride: effect of current density and vehicle formulation.
2001 Dec
[Dopamine agonists situation in Parkinson disease].
2001 Dec 1-15
Possible applications for dopaminergic agents following traumatic brain injury: part 2.
2001 Feb
Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist.
2001 Jan
Literature alert.
2001 Jul
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
2001 Jul
The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
2001 Jun
Newer dopamine agonists in the treatment of restless legs syndrome.
2001 May
Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study.
2001 May-Jun
Randomized clinical trials with added rescue medication: some approaches to their analysis and interpretation.
2001 Oct 30
DA agonists -- non-ergot derivatives: ropinirole: management of Parkinson's disease.
2002
Choosing the right dopamine agonist for patients with Parkinson's disease.
2002
'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect?
2002
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
2002
Two advances in the management of Parkinson disease.
2002 Aug
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group.
2002 Jan 23-30
Pergolide in the treatment of patients with early and advanced Parkinson's disease.
2002 Jan-Feb
GSK's Requip slow the loss of dopamine function in Parkinson's disease.
2002 Jul
Gateways to clinical trials.
2002 Jul-Aug
[Multiple latency test in a patient with episodes of sleep induced by pergolide].
2002 Jun 16-30
Is it time to abandon functional imaging in the study of neuroprotection?
2002 Mar
Alopecia induced by dopamine agonists.
2002 Mar 12
Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.
2002 Nov
Do dopamine agonists or levodopa modify Parkinson's disease progression?
2002 Nov
Dopamine agonists and neuroprotection in Parkinson's disease.
2002 Nov
Ropinirole for antidepressant-induced sexual dysfunction.
2002 Nov
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
2002 Nov
Neuroprotection in idiopathic Parkinson's disease.
2002 Oct
Do dopaminergic agents increase the daytime sleep propensity? Article reviewed: Effect of ropinirole on sleep onset. A randomized, placebo-controlled study in healthy volunteers.
2002 Sep
The timing of antiparkinsonian treatment reduction after subthalamic nucleus stimulation.
2003
[Sexual delinquency and Parkinson's disease].
2003 Apr
Current status of Parkinson's disease treatment in Korea.
2003 Aug
REAL and CALM: what have we learned?
2003 Jul
Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists.
2003 May
Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.
2003 Nov
Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum.
2003 Oct
Current treatment options for restless legs syndrome.
2003 Oct
Clinical strategies to prevent and delay motor complications.
2003 Sep 23
Patents

Sample Use Guides

Parkinson Disease: 0.25 mg PO q8hr for 1 week initially, then increased weekly by 0.25 mg q8hr; if necessary, after week 4, may be increased weekly by 1.5 mg/day up to 9 mg/day, then increased weekly by 3 mg/day up to 24 mg/day Restless Leg Syndrome: 0.25 mg/day PO 1-3 hr before bedtime; after day 2, may be increased to 0.5 mg/day PO; at end of week 1, increased to 1 mg/day, then increased weekly by 0.5 mg/day up to 4 mg/day
Route of Administration: Oral
Human SH-SY5Y neuroblastoma cells were grown to confluence in Dulbecco’s Modified Eagle’s media (DMEM) supplemented with 10% fetal calf serum, 100 mkg/mL penicillin, 100 mkg/mL streptomycin, 0.25 mkg/mL amphotericin B, and 0.01 mkM non-essential amino acids (Gibco Grand Island, NY, USA) and then sub-cultured for differentiation in 48 well Costar culture plates. For differentiation, the cells were grown in same media containing 10 mkM retinoic acid for 3 days; then the media was removed and replaced with media containing 160 nM of the phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA) for 3 days of differentiation. The cells were then administered a range doses of pramipexole, ropinirole and S32504 (10 nM to 1 mM) in DMEM for three days prior to addition of 1 mM MPP+. Following transfer of MPP+ to the media cells were tested every 24 h for 72 h for the cytotoxicity of MPP+ as measured by the MTT and LDH assays which accurately measure different aspects of apoptosis. In addition, we tested for the neuroprotective effects of a fixed dose of each drug (50 mkM) and a range of doses of S32504 on MPP+ induced apoptosis, and the effects of ropinirole alone (1 mM) as measured by DNA laddering.
Substance Class Chemical
Created
by admin
on Thu Jul 06 21:22:45 UTC 2023
Edited
by admin
on Thu Jul 06 21:22:45 UTC 2023
Record UNII
030PYR8953
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROPINIROLE
INN   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
Ropinirole [WHO-DD]
Common Name English
ROPINIROLE [MI]
Common Name English
NARAPIN
Common Name English
SK&F 101468
Code English
ROPITOR
Brand Name English
ROPINIROLE [USAN]
Common Name English
NSC-758917
Code English
ROPINIROLE [VANDF]
Common Name English
ropinirole [INN]
Common Name English
SK&F-101468
Code English
Classification Tree Code System Code
NCI_THESAURUS C38149
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
NDF-RT N0000175768
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
LIVERTOX NBK548175
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
NDF-RT N0000000117
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
WHO-ATC N04BC04
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
WHO-VATC QN04BC04
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID8045195
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
WIKIPEDIA
ROPINIROLE
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
LACTMED
Ropinirole
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
CHEBI
8888
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
NSC
758917
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
USAN
TT-138
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
PUBCHEM
5095
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
FDA UNII
030PYR8953
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
DRUG CENTRAL
2402
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
INN
6436
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
MERCK INDEX
M9658
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY Merck Index
EVMPD
SUB10380MIG
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
RXCUI
72302
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY RxNorm
DRUG BANK
DB00268
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
IUPHAR
7295
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
ChEMBL
CHEMBL589
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
NCI_THESAURUS
C61931
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
MESH
C046649
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
CAS
91374-21-9
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
DAILYMED
030PYR8953
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
HSDB
8252
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
SMS_ID
100000084378
Created by admin on Thu Jul 06 21:22:45 UTC 2023 , Edited by admin on Thu Jul 06 21:22:45 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
TARGET -> AGONIST
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC